Video

Dr. Kumar on Managing Toxicities in the MLN9708 Study

Shaji K. Kumar, MD, Division of Hematology, Mayo Clinic, talks about managing toxicities in the MLN9708 study.

Shaji K. Kumar, MD, Division of Hematology, Mayo Clinic, talks about managing toxicities in the MLN9708 study.

Kumar was the lead author on a phase I/II study analyzing MLN9708 in combination with lenalidomide and dexamethasone in previously untreated multiple myeloma patients. The study found that the recommended phase II dose showed antitumor activity and was well tolerated, with one peripheral neuropathy.

In most treatments, Kumar says, the main way to manage toxicity is to decrease the dosage. In the two patients that experienced peripheral neuropathy in the trial, their dosage was decreased and their condition improved.

<<<

View coverage from the 2012 ASH Meeting

Related Videos
Noa Biran, MD
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.
Toni K. Choueiri, MD
Neil J. Shah, MBBS
Noa Biran, MD
Alfred L. Garfall, MD, MS
Amrita Krishnan, MD, City of Hope
Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM)
Noa Biran, MD